Analysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) Price Target at $40.67

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $40.67.

Several research analysts recently issued reports on the company. HC Wainwright increased their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, November 5th. The Goldman Sachs Group raised their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a report on Monday, November 25th. TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $50.00 target price on the stock. Finally, StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, January 7th.

TG Therapeutics Trading Up 9.1 %

Shares of TGTX traded up $2.51 during midday trading on Tuesday, hitting $30.18. The stock had a trading volume of 4,147,541 shares, compared to its average volume of 3,124,046. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The stock's 50 day moving average is $31.55 and its 200 day moving average is $25.52. The firm has a market cap of $4.70 billion, a PE ratio of -301.77 and a beta of 2.24. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same period in the prior year, the business posted $0.73 earnings per share. TG Therapeutics's revenue was down 49.4% on a year-over-year basis. As a group, analysts forecast that TG Therapeutics will post 0.17 EPS for the current fiscal year.

Insider Buying and Selling

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares of the company's stock, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,358 shares of company stock worth $781,497 in the last 90 days. 10.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. NBC Securities Inc. increased its holdings in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 485 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the 2nd quarter worth approximately $35,000. Blue Trust Inc. raised its position in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after buying an additional 849 shares during the last quarter. ORG Wealth Partners LLC acquired a new stake in TG Therapeutics during the 3rd quarter valued at approximately $53,000. Finally, Values First Advisors Inc. purchased a new stake in shares of TG Therapeutics in the 3rd quarter valued at $58,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.